Kerri Smith, MD
Critical Care Medicine · Philadelphia, PANPI 1821167941
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,103 of the $30,335 with a category attached, or 89.3%. 5 manufacturers reported payments, led by Merck at 58.0% of the total. 2025 is the largest year on record at $17,701, more than ten times the $118 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $777.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- United Therapeutics Corporation$13K
- Medline Industries LP$43
- Boehringer Ingelheim$19
- Gilead$11
Across 34 payments — averaging $3627.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$53K
- United Therapeutics Corporation$33K
- Actelion Pharmaceuticals US, Inc.$32K
- Janssen Research & Development, LLC$6K
What the payments were for
- Consulting fees$27,10389%
- Travel & lodging$1,8356%
- Food & beverage$1,3544%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 21 | $17,587 |
| United Therapeutics Corporation | 15 | $12,674 |
| Medline Industries LP | 1 | $43 |
| Boehringer Ingelheim | 1 | $19 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,335 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 278 | $3,577,651 |
| UptraviSelexipag | 77 | $1,751,474 |
| AdempasRiociguat | 63 | $857,642 |
| LetairisAmbrisentan | 51 | $631,185 |
| Ambrisentan | 151 | $495,916 |
| WinrevairSotatercept-Csrk | 29 | $415,625 |
| Tyvaso DpiTreprostinil | 12 | $296,725 |
| RemodulinTreprostinil Sodium | 19 | $246,893 |
| Bosentan | 29 | $244,646 |
| Tadalafil | 303 | $241,007 |
| AdcircaTadalafil | 42 | $176,550 |
| Sildenafil Citrate | 114 | $41,428 |
| EliquisApixaban | 28 | $39,625 |
| XareltoRivaroxaban | 18 | $16,925 |
| Spiriva RespimatTiotropium Bromide | 25 | $16,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadLetairis | $11 | $631,18551 claims |
| United Therapeutics CorporationRemodulin, Adcirca | $12,674 | $423,44361 claims |
| MerckWinrevair | $17,587 | $415,62529 claims |
| Boehringer IngelheimSpiriva Respimat | $19 | $16,10025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Philadelphia
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Michael BeersPhiladelphia$28K
- Daniel DorganPhiladelphia$23K
- Belinda Rivera-LebronPhiladelphia$18K
- Kevin MaPhiladelphia$15K
- Joshua DiamondPhiladelphia$13K
- Gregory TinoPhiladelphia$9K
- Anthony LanfrancoPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.